Seronegative Oligoarthritis of the Knee Study (SOKS) (SOKS)

Intra-articular and Intravenous Infliximab in the Treatment of Resistant Seronegative Oligoarthritis of the Knee

The aim of this study is to establish the efficacy and duration of effect of intra-articular (IA) infliximab vs intravenous infliximab vs current standard care (IA steroid injections) in seronegative oligoarthritis. All patients will have seronegative arthritis affecting less than 5 joints but including at least one knee. 10 patients will receive IA infliximab injections to the affected knee, 10 will receive IA steroid injections to the affected knee and 10 will receive a course of intravenous infliximab. Patients will not be aware of their group as this is a placebo-controlled study.

Study Overview

• Status: Terminated
• Conditions: Spondylarthropathies
• Intervention / Treatment: Drug: methylprednisolone; Drug: Infliximab; Drug: Infliximab

• Study Type: Interventional
• Enrollment (Actual): 1
• Phase: Phase 2

Contacts and Locations

Study Locations

• United Kingdom
  • West Yorkshire
    • Leeds, West Yorkshire, United Kingdom, LS7 4SA
      • Leeds Teaching Hospitals NHS Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Inflammatory oligoarthritis (4 or less active joints) with at least one swollen knee joint of at least 3 months duration
• Rheumatoid factor and anti-CCP Ab negative
• Either arthritis onset at <45 years of age, or arthritis onset at ≥45 years of age with early morning stiffness>30mins or raised inflammatory markers
• If under 40 years of age, clinical exclusion of a diagnosis of gout.
• If 40 years or older at screening, a prior normal examination of synovial fluid from the affected joint excluding crystal arthropathy or infection.
• Failure of methotrexate (inefficacy after >3 month trial, intolerance or contra-indication)
• Have the capacity to understand and sign an informed consent form.
• Gender: male or female
• 18 years of age or over.
• Women must be either postmenopausal (no menstrual period for a minimum of 1 year) or surgically sterilized or in use of adequate birth control measures and have a negative serum pregnancy test on entry in the study.
• Men and women of childbearing potential must use adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilization) for the duration of the study and should continue such precautions for 6 months after receiving the last infusion.
• Are considered eligible according to the tuberculosis (TB) eligibility assessment, screening, and early detection of reactivation rules defined in the protocol

• The screening laboratory test results must meet the following criteria

  • WBC (white blood cell count): >3.5 x 109/L
  • ANC (absolute neutrophil count): >1.5 x 109/L
  • Hemoglobin: >10g/dL
  • Platelets: >120 x 109/L
  • SGPT (ALT - alanine aminotransferase) < 1.5 times upper normal limit (i.e. 60iu/L)
• Have no history of latent or active TB prior to screening. An exception is made for subjects with a history of latent TB and documentation of having completed appropriate treatment for latent TB (see Appendix 3) within 3 years prior to the first administration of study agent. It is the responsibility of the investigator to verify the adequacy of previous anti-tuberculous treatment and provide appropriate documentation.
• Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination.
• Have had no recent close contact with a person with active TB or, if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB prior to the first administration of study agent.
• Within 6 weeks prior to the first administration of study agent, either have a negative QuantiFeron test result (see Appendix 3) or have a newly identified positive QuantiFeron test result during screening in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated prior to the first administration of study agent.
• Have a chest radiograph (posterior-anterior view and if required, a lateral view), taken within 3 months prior to the first administration of study agent and read by a qualified radiologist, with no evidence of current, active TB or old, inactive TB.

Exclusion Criteria:

• Grade 4 osteoarthritis (Kellgren-Lawrence score) on plain radiograph of the knee
• Rheumatoid Arthritis (defined by the ACR criteria for the diagnosis of RA, 1987)
• Ankylosing Spondylitis (defined by the modified New York Criteria)
• Clinical diagnosis of gout or previous evidence of crystal arthropathy on synovial fluid aspirates
• Women who are pregnant, nursing, or planning pregnancy within 6 months after the last infusion (this includes father's who plan on fathering a child within 6 months after their last infusion).
• Have had any previous treatment with biological therapies.
• History of receiving human/murine recombinant products or a known allergy to murine products. A known allergy to murine product is definitely an exclusion criterion
• Previous intra-muscular, intra-articular or intra-venous steroids within 4 weeks prior to baseline.
• Previous oral steroids at a dose >10mg/day prednisolone or equivalent for 4 weeks prior to baseline.
• Documentation of seropositive for human immunodeficiency virus (HIV).
• Documentation of a positive test for hepatitis B surface antigen or hepatitis C.
• Have a history of alcohol or substance abuse within the preceding 6 months that, in the opinion of the investigator, may increase the risks associated with study participation or study agent administration, or may interfere with interpretation of results.
• Have a known history of serious infections (e.g., hepatitis, pneumonia, or pyelonephritis) in the previous 3 months.
• Have or have had an opportunistic infection (e.g., herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening
• Have had a Bacille Calmette-Guérin (BCG) vaccination within 12 months of screening.
• Are considered ineligible according to the TB eligibility assessment, screening, and early detection of reactivation rules described in Appendix 3.
• Have a chest radiograph within 3 months prior to the first administration of study agent that shows an abnormality suggestive of a malignancy or current active infection.
• Have a history of lymphoproliferative disease, including lymphoma or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location (e.g., nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic area), or splenomegaly.
• Currently have any known malignancy other than the condition being treated or have a history of malignancy, with the exception of basal cell or squamous cell carcinoma of the skin that has been fully excised with no evidence of recurrence.
• Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.
• Are unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access.
• Use of any investigational drug within 30 days prior to screening or within 5 half-lives of the investigational agent, whichever is longer.
• Presence of a transplanted solid organ (with the exception of a corneal transplant > 3 months prior to screening).
• Have a concomitant diagnosis or history of congestive heart failure.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: IA steroid; Intra-articular injection of steroid (80mg depomedrone)	Drug: methylprednisolone; intra-articular injection of methylprednisolone (80mg given at baseline only); Other Names: depomedrone
EXPERIMENTAL: IA infliximab; intra-articular injection of 100mg infliximab	Drug: Infliximab; intra-articular injection of 100mg infliximab given at baseline only; Other Names: remicade; Drug: Infliximab; intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14; Other Names: remicade
EXPERIMENTAL: IV infliximab; intravenous infusions of infliximab given at 0, 2, 6 and 14 weeks at a dose of 5mg/kg (patient body weight)	Drug: Infliximab; intra-articular injection of 100mg infliximab given at baseline only; Other Names: remicade; Drug: Infliximab; intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14; Other Names: remicade

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ultrasound Synovitis Score	reduction of ultrasound synovitis score of the affected knee at 8 weeks following intiation of treatment	8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
US Synovitis Score	Change in US synovitis score of the affected knee at 2 and 8 weeks after treatment initiation	2 weeks
Pain Visual Analogue Scale	Change in patient's assessment of pain by a 100mm visual analogue score	2 weeks
Psoriatic Arthritis Quality of Life Scale (PsQOL)	Change in PsQOL score from baseline	2 weeks
Rheumatoid Arthritis Outcome Score (RAOS)	Change in RAOS questionnaire score	2 weeks
US Synovitis Score	Change in US synovitis score of the affected knee at 2 and 8 weeks after treatment initiation	16 weeks
Pain Visual Analogue Scale	Change in patient's assessment of pain by a 100mm visual analogue score	6 weeks
Pain Visual Analogue Scale	Change in patient's assessment of pain by a 100mm visual analogue score	8 weeks
Pain Visual Analogue Scale	Change in patient's assessment of pain by a 100mm visual analogue score	14 weeks
Pain Visual Analogue Scale	Change in patient's assessment of pain by a 100mm visual analogue score	16 weeks
Psoriatic Arthritis Quality of Life Scale (PsQOL)	Change in PsQOL score from baseline	26 weeks
Psoriatic Arthritis Quality of Life Scale (PsQOL)	Change in PsQOL score from baseline	6 weeks
Psoriatic Arthritis Quality of Life Scale (PsQOL)	Change in PsQOL score from baseline	8 weeks
Psoriatic Arthritis Quality of Life Scale (PsQOL)	Change in PsQOL score from baseline	14 weeks
Psoriatic Arthritis Quality of Life Scale (PsQOL)	Change in PsQOL score from baseline	16 weeks
Rheumatoid Arthritis Outcome Score (RAOS)	Change in RAOS questionnaire score	6 weeks
Rheumatoid Arthritis Outcome Score (RAOS)	Change in RAOS questionnaire score	8 weeks
Rheumatoid Arthritis Outcome Score (RAOS)	Change in RAOS questionnaire score	14 weeks
Rheumatoid Arthritis Outcome Score (RAOS)	Change in RAOS questionnaire score	16 weeks
Rheumatoid Arthritis Outcome Score (RAOS)	Change in RAOS questionnaire score	26 weeks

Collaborators and Investigators

• Sponsor: University of Leeds
• Collaborators: Centocor, Inc.
• Investigators: Principal Investigator: Philip G Conaghan, FRCP, University of Leeds

Study record dates

Study Major Dates

• Study Start: September 1, 2010
• Primary Completion (ACTUAL): August 1, 2011
• Study Completion (ACTUAL): August 1, 2011

Study Registration Dates

• First Submitted: October 6, 2010
• First Submitted That Met QC Criteria: October 6, 2010
• First Posted (ESTIMATE): October 7, 2010

Study Record Updates

• Last Update Posted (ESTIMATE): May 13, 2016
• Last Update Submitted That Met QC Criteria: May 10, 2016
• Last Verified: May 1, 2016

More Information

Terms related to this study

• Keywords: infliximab; intraarticular; seronegative; oligoarthritis
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Arthritis; Spinal Diseases; Bone Diseases; Spondylarthritis; Spondylitis; Spondylarthropathies; Physiological Effects of Drugs; Autonomic Agents; Peripheral Nervous System Agents; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Neuroprotective Agents; Protective Agents; Dermatologic Agents; Prednisolone; Methylprednisolone Acetate; Methylprednisolone; Methylprednisolone Hemisuccinate; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Infliximab
• Other Study ID Numbers: 2009-015810-23